Dutch CRO Viroclinics acquired by PE firm

By Melissa Fassbender

- Last updated on GMT

(Image: Viroclinics Biosciences)
(Image: Viroclinics Biosciences)

Related tags Investment

Viroclinics Biosciences is expanding its service offering – and eyeing acquisition – following an investment by Parcom Capital.

The mid-market private equity (PE) firm Parcom Capital acquired the virology contract research organization (CRO) from Glide Healthcare Partners, which bought a majority stake​ in the company in 2013.

We are entering a new growth phase and the acquisition by Parcom Capital will give us the opportunity to expand our service portfolio​,” Viroclinics Biosciences CEO, Bob van Gemen told Outsourcing-Pharma.com.

With Parcom’s Capital platform, our growth rate is accelerated. This means that we are looking into the option of acquiring other companies with specialist knowledge​.”

van Gemen said potential new services include: vaccine ingredients production, new test development for viral targets, and big data

The major benefit [of the acquisition] is that our service offering is expanded for our customers​,” added van Gemen.

Specifically, Viroclinic – which has more than 100 employees globally – is looking to portfolio in other target areas, such as Hepatitis, Polio, SARS, Avian/ Bird Flu, and Rabies.

Financial details of the acquisition were not disclosed.

Related news

Related products

Follow us


View more